Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.
about
Optimal combination of antiangiogenic therapy for hepatocellular carcinomaEffects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948)Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selectionA network model for angiogenesis in ovarian cancer.Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.Current status of bevacizumab in advanced ovarian cancerAngiogenesis-related pathways in the pathogenesis of ovarian cancerMolecular Biomarkers of Response to Antiangiogenic Therapy for Cancer.Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth.Placental growth factor in cancer.Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin.
P2860
Q26799458-8015E253-F911-4553-A213-C70AE1EB9146Q28732214-CFC8D380-734B-4883-BD72-650F2789F5F8Q34916073-C92FDC6D-2243-4289-ACFA-D28D37FAC86EQ35534413-ED21E539-7FFD-4505-8F31-126F4AB6EFEFQ35954103-4AAD1B2E-432B-4800-B15F-D062A1B304ECQ37048186-F32A6B20-0D63-4279-97F2-1E6A6E6CA230Q37139109-3075209F-4C59-41E6-B2ED-6CEB9026D32BQ37377316-B2FB255A-16F0-4C33-84B5-711E1BD1BCCAQ37483716-172637BC-808A-4221-ABE1-907D63906883Q38258289-61CB8B22-E8DC-4232-92A1-B54492129659Q45916912-8EB34C27-54C7-410A-B6D6-E55BAEC6EAC1
P2860
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Safety, Efficacy, and Biomarke ...... Recurrent Müllerian Carcinoma.
@ast
Safety, Efficacy, and Biomarke ...... Recurrent Müllerian Carcinoma.
@en
type
label
Safety, Efficacy, and Biomarke ...... Recurrent Müllerian Carcinoma.
@ast
Safety, Efficacy, and Biomarke ...... Recurrent Müllerian Carcinoma.
@en
prefLabel
Safety, Efficacy, and Biomarke ...... Recurrent Müllerian Carcinoma.
@ast
Safety, Efficacy, and Biomarke ...... Recurrent Müllerian Carcinoma.
@en
P2093
P2860
P1476
Safety, Efficacy, and Biomarke ...... Recurrent Müllerian Carcinoma.
@en
P2093
Carolyn N Krasner
Dan G Duda
Emmanuelle di Tomaso
Kenneth S Cohen
Marek Ancukiewicz
Marsha A Moses
Neil S Horowitz
Rakesh K Jain
Richard T Penson
Suzanne Berlin
P2860
P356
10.1016/J.CLOC.2011.04.003
P407
P577
2011-06-01T00:00:00Z